Tharimmune announces positive results for novel oral monoclonal antibody th023 targeting tumor necrosis factor-alpha

Bridgewater, nj / access newswire / march 24, 2025 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, th023. in a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha (tnf-Α) inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection (~3-5Μg/ml).
THAR Ratings Summary
THAR Quant Ranking